Investigational drug · Phase 2
AUP1602-C
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Diabetic Foot Ulcer.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "AUP1602-C"
First trial start
2023
Jul 21, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AUP1602-C", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Foot Ulcer
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "AUP1602-C" as an intervention, largest first.
Aurealis OyIndustry
NCT06111183 · 64 participants · Start Jul 21, 2023 · Primary completion Nov 28, 2025
Drug: AUP1602-C · For: Diabetic Foot Ulcer
Sites: Münster, Germany; Pirna, Germany; Arezzo, Italy · 10 sites in all
Aurealis OyIndustry
NCT04281992 · 26 participants · Start Jan 28, 2020 · Primary completion Mar 20, 2023
Drug: AUP1602-C · For: Diabetic Foot Ulcer
Sites: Hanover, Germany; Lodz, Poland
Newest research
PubMed records naming it or its code names, newest first.
- Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study.
Schindler C, Mikosiski J, Mikosiski P, et al. · Ther Adv Endocrinol Metab 2024
- Four in one-Combination therapy using live Lactococcus lactis expressing three therapeutic proteins for the treatment of chronic non-healing wounds.
Kurkipuro J, Mierau I, Wirth T, et al. · PLoS One 2022
Also in development for Diabetic Foot Ulcer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.